-
101.发明申请公开(公告)号：US20180094043A1
公开(公告)日：2018-04-05
申请号：US15842381
申请日：2017-12-14
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K39/00 , C12N5/0783 , C07K14/47 , G01N33/569 , C12N9/64 , C07K14/00 , G01N33/50 , A61K38/17 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/68 , C07K16/30 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
102.发明申请公开(公告)号：US20180037629A1
公开(公告)日：2018-02-08
申请号：US15789771
申请日：2017-10-20
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , C12Q1/68 , A61K39/00 , A61K45/06 , C12N5/0783 , C12N9/64 , G01N33/50 , G01N33/566 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , C07K16/30 , A61K38/08 , G01N33/569 , A61K38/17
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
103.发明申请公开(公告)号：US20170305992A1
公开(公告)日：2017-10-26
申请号：US15638678
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , C12Q1/68 , A61K45/06 , C12N5/0783 , C12N9/64 , C07K7/02 , C07K7/06 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , C07K16/30 , A61K38/08 , G01N33/566 , G01N33/569 , A61K39/00
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
104.发明申请公开(公告)号：US20170253633A1
公开(公告)日：2017-09-07
申请号：US15445461
申请日：2017-02-28
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , C07K16/18 , G01N33/68 , A61K35/17 , A61K39/00 , C12N15/115 , C07K7/06 , C07K14/725
CPC classification number: C07K7/08 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K2319/00 , C12N15/115 , C12N2310/16 , G01N33/6893 , G01N2800/52
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
105.发明申请公开(公告)号：US20170165337A1
公开(公告)日：2017-06-15
申请号：US15374054
申请日：2016-12-09
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N5/0783 , C07K16/30 , C07K14/725 , C12N15/115 , C07K7/06 , C07K14/47
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K2317/34 , C12N5/0636 , C12N15/115 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
106.发明申请公开(公告)号：US20170037107A1
公开(公告)日：2017-02-09
申请号：US15199244
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/705 , A61K39/00 , C12N5/0783 , C07K16/28 , C07K16/30 , C07K14/74 , C07K14/725 , C12N15/115
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
107.发明申请公开(公告)号：US20170037093A1
公开(公告)日：2017-02-09
申请号：US15199338
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K39/00 , C07K14/74 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20160355550A1
公开(公告)日：2016-12-08
申请号：US15226002
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20160289296A1
公开(公告)日：2016-10-06
申请号：US15082920
申请日：2016-03-28
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
CPC classification number: A61K39/0011 , A61K35/17 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G06F19/20
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20140271692A1
公开(公告)日：2014-09-18
申请号：US14138421
申请日：2013-12-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver SCHOOR , Claudia TRAUTWEIN
CPC classification number: A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。
-
-
-
-
-
-
-
-
-
Search Results
612
records
(took 0.066 seconds)
